# A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions

> **NCT00864981** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 32 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
- **DRUG:** WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline

## Key facts

- **NCT ID:** NCT00864981
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00864981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00864981, "A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00864981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*